Quick Answer
Entrada Therapeutics, Inc. reported Total Assets of $377.38 million for the year ending 2025.
- Entrada Therapeutics, Inc. showed a decrease of -28.3% in Total Assets from 2024 to 2025.
- This data is from Entrada Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $132.40 million | Q1 2022: $316.70 million | Q2 2022: $295.92 million | Q3 2022: $274.46 million | Q1 2023: $475.57 million | Q2 2023: $493.98 million | Q3 2023: $485.03 million | Q1 2024: $510.84 million | Q2 2024: $581.96 million | Q3 2024: $554.59 million | Q1 2025: $486.48 million | Q2 2025: $448.78 million | Q3 2025: $412.90 million.
- Over the full 6 years of available data (2020 to 2025), Entrada Therapeutics, Inc.'s Total Assets has grown by 767.0%.
- Historical annual values: Fiscal year 2025: $377.38 million | Fiscal year 2024: $526.32 million | Fiscal year 2023: $469.19 million | Fiscal year 2022: $252.06 million | Fiscal year 2021: $305.83 million | Fiscal year 2020: $43.53 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: